Retatrutide (LY3437943, also referred to informally as "reta peptide") is a synthetic 39-amino-acid peptide developed by Eli Lilly that acts simultaneously on three distinct metabolic receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and the glucagon receptor
Dark diarrhea with bleeding during pregnancy is the underlying symptom of GERD
This surge in obesity rates is closely linked to a heightened risk of chronic diseases such as type 2 diabetes, cardiovascular diseases, and certain cancers
Use SingleCare SingleCares discounts can take up to 80% off the price of some medications and knock hundreds off the price of Ozempic
Understanding how quickly semaglutide begins working helps set realistic expectations for research timelines
To make sure you get enough, eat your protein first (before you get too full)